Related Experiment Videos
[Metergoline in hyperprolactinemic breast cancer: a phase II study]
Onkologie
|October 1, 1986
Summary
Metergoline, a dopamine receptor agonist, effectively reduced high prolactin levels in metastatic breast cancer patients. This treatment showed mild side effects like dizziness and nausea at a lower dose.
Area of Science:
- Endocrinology
- Medical Oncology
Context:
- Hyperprolactinemia is a condition of elevated prolactin levels.
- Metastatic breast cancer can be associated with hyperprolactinemia.
Purpose:
- To investigate the prolactin release inhibiting action of metergoline.
- To assess the efficacy and side effects of metergoline in patients with metastatic breast cancer and hyperprolactinemia.
Summary:
- Metergoline, a dopamine receptor agonist, was administered daily at 12 mg orally for 30 days to 16 patients with metastatic breast cancer and hyperprolactinemia.
- The treatment significantly lowered prolactin levels from 1076 +/- 171 mU/l at baseline to 249 +/- 46 mU/l on day 29.
- Mild side effects, including dizziness and nausea, were observed when initiating treatment at 4 mg/day.
Impact:
- Metergoline demonstrates significant efficacy in managing hyperprolactinemia in metastatic breast cancer patients.
- The findings suggest metergoline as a potential therapeutic option for this patient population, with manageable side effects.